Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Next Previous
Trial Profile

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Saposin C (Primary)
  • Indications Colorectal cancer; Ependymoma; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Glioma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bexion Pharmaceuticals

Most Recent Events

  • 31 Oct 2024 According to the Bexion Pharmaceuticals media release, results from this study were published in Clinical Cancer Research, an American Association of Clinical Research (AACR) journal.
  • 31 Oct 2024 Results presented in thecBexion Pharmaceuticals Media Release.
  • 19 Apr 2023 Results assessing whether BXQ-350 alleviated CIPN symptoms in several patients soon after receiving BXQ-350, presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top